Trial Profile
A Phase II study in patients with locally advanced pancreatic carcinoma: ARC-II- Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Nelfinavir (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 25 Jul 2015 Status changed from discontinued to completed as per European Clinical Trials Database record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 05 Jul 2012 Roche added as associations as reported in the European Clinical Trials Database record.